Q-omics provides the consensus-scored MRPL37P1 profile across patient tissues and cancer cell-line models. MRPL37P1 expression is associated with patient survival in 18 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, MRPL37P1 is differentially expressed in 7, with the highest sampling consensus in KIRC. Additionally, MRPL37P1 RNA expression shows 7,596 significant protein co-abundance associations, with the highest sampling consensus in UCEC. Together, these results highlight KIRC, and UCEC as cancer lineages where MRPL37P1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MRPL37P1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MRPL37P1 survival associations across molecular data types. MRPL37P1 RNA expression shows survival associations in the most cancer types (18). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MRPL37P1 RNA expression–survival associations across cancer types. High MRPL37P1 expression shows unfavorable associations in KIRC, LIHC, ACC, LAML and TGCT, but favorable associations in LUAD. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for MRPL37P1 RNA expression.
This table summarizes MRPL37P1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 7. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for MRPL37P1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MRPL37P1 shows lower tumor expression in KICH and BRCA and higher tumor expression in KIRC, STAD, HNSC and CHOL. The KIRC box plot shows higher MRPL37P1 RNA expression in tumor versus normal tissue (log2 FC = +0.064, t-test p = .012).
This table shows molecular features associated with MRPL37P1 in patient tissues and cancer cell lines. In patient samples, MRPL37P1 shows the broadest associations at the RNA and protein expression levels, with UCEC recurring as the lineage with the largest associated feature set.
